This study is looking at people who have had a non-cardioembolic ischemic stroke, which is a type of stroke caused by a blocked blood vessel in the brain that is not related to heart rhythm problems. The study will test three different medications that help prevent blood clots: ticlopidine hydrochloride, clopidogrel, and acetylsalicylic acid (also known as aspirin). These medications work by preventing small blood cells called platelets from sticking together and forming clots. The purpose of the study is to show that choosing the right antiplatelet drug for each person based on their individual characteristics can reduce the number of major heart and blood vessel problems that happen within 12 months, compared to the standard way of prescribing these medications.
People in this study will have had their stroke within the past two weeks and will be taking either one or two antiplatelet medications as part of their treatment to prevent another stroke. The study will compare different approaches to selecting which antiplatelet medication works best for each person. During the study, participants will be followed for 12 months, with check-ups at 3 months and 12 months to see how well they are taking their medication and how well the medication is working. The study will also look at whether there are differences in how men and women respond to these treatments.
The main thing researchers will measure is how many people have another stroke, a heart attack, or die from heart-related causes within 12 months. They will also look at whether people have any bleeding problems, how well people stick to taking their medication, and how well people can function in their daily lives after 12 months. The study will examine genetic factors that might affect how people respond to these medications and will track all major health events that occur during the treatment period.
Italy 
